Janux Therapeutics, Inc. (NASDAQ:JANX) Given Average Rating of “Buy” by Analysts

Janux Therapeutics, Inc. (NASDAQ:JANX) has earned an average rating of “Buy” from the twelve analysts that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $92.44.

Several equities analysts recently commented on JANX shares. Lifesci Capital raised shares of Janux Therapeutics to a “strong-buy” rating in a report on Friday, December 27th. Leerink Partners raised their price objective on Janux Therapeutics from $79.00 to $91.00 and gave the company an “outperform” rating in a research note on Tuesday, December 3rd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $200.00 price objective on shares of Janux Therapeutics in a report on Wednesday, December 11th. Stifel Nicolaus increased their target price on Janux Therapeutics from $70.00 to $115.00 and gave the company a “buy” rating in a report on Tuesday, December 3rd. Finally, Wedbush reaffirmed an “outperform” rating and issued a $76.00 price target (up from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th.

Insider Buying and Selling

In related news, insider Andrew Hollman Meyer sold 13,334 shares of the stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $54.88, for a total value of $731,769.92. Following the completion of the transaction, the insider now directly owns 82,139 shares of the company’s stock, valued at $4,507,788.32. This represents a 13.97 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO David Alan Campbell sold 5,000 shares of Janux Therapeutics stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $60.00, for a total value of $300,000.00. Following the sale, the chief executive officer now directly owns 293,054 shares in the company, valued at approximately $17,583,240. The trade was a 1.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 25,002 shares of company stock valued at $1,279,953 over the last quarter. 29.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Janux Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. boosted its holdings in shares of Janux Therapeutics by 77.7% during the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company’s stock valued at $54,000 after buying an additional 442 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in Janux Therapeutics during the 4th quarter valued at about $59,000. Avanza Fonder AB bought a new stake in Janux Therapeutics during the fourth quarter worth about $139,000. Meeder Asset Management Inc. purchased a new stake in Janux Therapeutics in the fourth quarter worth about $159,000. Finally, Tower Research Capital LLC TRC increased its stake in shares of Janux Therapeutics by 878.8% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,827 shares of the company’s stock valued at $205,000 after purchasing an additional 3,436 shares in the last quarter. Institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Trading Down 2.3 %

JANX opened at $29.10 on Monday. The stock has a market capitalization of $1.72 billion, a P/E ratio of -24.87 and a beta of 3.23. The stock has a 50-day moving average price of $35.60 and a 200-day moving average price of $46.01. Janux Therapeutics has a 12-month low of $28.91 and a 12-month high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last issued its earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. On average, equities research analysts predict that Janux Therapeutics will post -1.38 EPS for the current year.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.